Yenson Lau

Yenson Lau

Auto-generated profile, based on publicly available information

Yenson Lau

Layer 6 AI

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2020 in Physical Review D
Verified
Journal Article
Closed access
PDF file
RCRobert E. Colgan
Robert E. Colgan
KCK. Rainer Corley
K. Rainer Corley
YLYenson Lau
Yenson Lau
IBImre Bartos
Imre Bartos
JWJohn N. Wright
John N. Wright
SMSzabolcs Márka
Szabolcs Márka
The LIGO observatories detect gravitational waves through monitoring changes in the detectors’ length down to below 10−19  m/Hz variations—a small fraction of the size of the atoms that make up the detector. To achieve this sensitivity, the detector and its environment need to be closely monitored. Beyond the gravitational-wave data stream, LIGO continuously records hundreds of thousands of channels of environmental and instrumental data in order to monitor for possibly minuscule variations that contribute to the detector noise. A particularly challenging issue is the appearance in the gravitational wave signal of brief, loud noise artifacts called “glitches,” which are environmental or instrumental in origin but can mimic true gravitational waves and therefore hinder sensitivity. Currently, they are primarily identified by analysis of the gravitational-wave data stream, and auxiliary data channels often provide corroborating evidence. Here we present a machine learning approach that can identify glitches by considering all environmental and detector data channels, a task that has not previously been pursued due to its scale and the number of degrees of freedom within gravitational-wave detectors. The presented method is capable of reducing the gravitational-wave detector network’s false alarm rate and improving the LIGO instruments, consequently enhancing detection confidence.

13 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
YLYenson Lau
Yenson Lau
JGJahir M. Gutierrez
Jahir M. Gutierrez
MVMaksims Volkovs
Maksims Volkovs
SZSaba Zuberi
Saba Zuberi
Leishmanisis, a neglected tropical disease caused by protozoan parasites of the genus Leishmania , affects millions of individuals living in poverty across the world and is second to malaria in parasitic causes of death. Although current drugs for treating leishmaniasis exist, these are either highly toxic, ineffective, or expensive. For this reason, there is an urgent need to identify affordable, safer, and more effective treatments. Drug repurposing is a promising method for identifying existing molecules with the potential to treat leishmaniasis. Here, we present a deep learning model for drug repurposing based on hyperbolic graph neural networks. We leverage experimentally validated protein-drug interactions and molecular descriptors across three different parasites to train and validate our model. The final network model shows significant gains over the best baseline model, with an 11.6% increase in precision of the top scoring 0.5% protein-drug pairs. Finally, our model identified two experimental drugs that could target three L. major proteins involved in drug resistance and cell cycle regulation, which play an essential role in ensuring the parasite’s survival inside the host. Author summary: Leishmanisis is a deadly and neglected tropical disease. Current treatments are ineffective, highly toxic, and unaffordable for the majority of affected individuals who live in extreme poverty. To accelerate the discovery and development of novel treatments against this disease, we develop a model that proposes existing drugs with the potential to treat leishmaniasis. Our methodology is based on hyperbolic graph neural networks, a class of deep learning models that can incorporate protein-drug interaction information from similar but well-studied parasites, in addition to utilizing chemical and molecular features. Empirically, this additional information leads to improved predictions of drug interactions with L. major proteins. Overall, the protein-drug pairs predicted by our model suggests two existing drugs that could target essential pathways for growth and survival of Leishmania parasites, which could be exploited either as a booster to increase the therapeutic effect of an existing anti-leishmaniasis drug, or as a novel chemotherapeutic treatment against the disease.